Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207560024> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3207560024 endingPage "634" @default.
- W3207560024 startingPage "628" @default.
- W3207560024 abstract "To evaluate the effectiveness of benralizumab in patients with the eosinophilic phenotype of severe asthma in real clinical practice after a year of therapy. Methods. During Benralizumab therapy, 13 patients with severe eosinophilic asthma (average age – 55.44 ± 7.18 years old) were examined twice: before the treatment and after 1 year of benralizumab therapy. The assessment included collection of complaints, medical history, current therapy, Asthma Control Questionnaire (ACQ-5) test, absolute blood count of eosinophils, spirometry. Results. All patients initially had pronounced eosinophilia of 577.5 ± 356.4 cells/μl. After 1 year of using benralizumab, the eosinophil count decreased by 96.15%. During therapy, the ACQ-5 index decreased from 1.63 ± 0.62 to 0.73 ± 0.41 in the study patients, which corresponded to the achievement of asthma control. The forced expiratory volume in 1 second (FEV1) increased by 23 %. The number of exacerbations decreased by 58.09%. 12 (92.31%) patients were on oral corticosteroids (OCS) (10 ± 2.17 mg of prednisolone daily) before benralizumab therapy. All subjects noted a decrease in night and day symptoms over time and were able to reduce the use of OCS. 5 (38.46%) patients achieved complete elimination of daily OCS use, 7 (53.84%) patients were able to reduce their daily OCS dose. Conclusion. Benralizumab therapy as an add-on maintenance treatment in patients with eosinophilic phenotype of severe asthma contributes to a significant decrease in peripheral blood eosinophils, which mediates an improvement in asthma control, an increase in FEV 1 , a reduction in the number of exacerbations, and a decrease in the need for the OCS usage. Careful monitoring of long-term adverse events is necessary during treatment with benralizumab." @default.
- W3207560024 created "2021-10-25" @default.
- W3207560024 creator A5053329547 @default.
- W3207560024 creator A5055527443 @default.
- W3207560024 creator A5071644965 @default.
- W3207560024 creator A5074210144 @default.
- W3207560024 date "2021-10-20" @default.
- W3207560024 modified "2023-10-18" @default.
- W3207560024 title "The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice" @default.
- W3207560024 cites W1991641875 @default.
- W3207560024 cites W2094189191 @default.
- W3207560024 cites W2142648568 @default.
- W3207560024 cites W2546040128 @default.
- W3207560024 cites W2619633721 @default.
- W3207560024 cites W2810825824 @default.
- W3207560024 cites W2963852476 @default.
- W3207560024 doi "https://doi.org/10.18093/0869-0189-2021-31-5-628-634" @default.
- W3207560024 hasPublicationYear "2021" @default.
- W3207560024 type Work @default.
- W3207560024 sameAs 3207560024 @default.
- W3207560024 citedByCount "2" @default.
- W3207560024 countsByYear W32075600242022 @default.
- W3207560024 countsByYear W32075600242023 @default.
- W3207560024 crossrefType "journal-article" @default.
- W3207560024 hasAuthorship W3207560024A5053329547 @default.
- W3207560024 hasAuthorship W3207560024A5055527443 @default.
- W3207560024 hasAuthorship W3207560024A5071644965 @default.
- W3207560024 hasAuthorship W3207560024A5074210144 @default.
- W3207560024 hasBestOaLocation W32075600241 @default.
- W3207560024 hasConcept C126322002 @default.
- W3207560024 hasConcept C142724271 @default.
- W3207560024 hasConcept C203014093 @default.
- W3207560024 hasConcept C2776042228 @default.
- W3207560024 hasConcept C2776694085 @default.
- W3207560024 hasConcept C2777037409 @default.
- W3207560024 hasConcept C2777129736 @default.
- W3207560024 hasConcept C2777832160 @default.
- W3207560024 hasConcept C2778283404 @default.
- W3207560024 hasConcept C2779185760 @default.
- W3207560024 hasConcept C2779758542 @default.
- W3207560024 hasConcept C2780333948 @default.
- W3207560024 hasConcept C71924100 @default.
- W3207560024 hasConcept C90924648 @default.
- W3207560024 hasConceptScore W3207560024C126322002 @default.
- W3207560024 hasConceptScore W3207560024C142724271 @default.
- W3207560024 hasConceptScore W3207560024C203014093 @default.
- W3207560024 hasConceptScore W3207560024C2776042228 @default.
- W3207560024 hasConceptScore W3207560024C2776694085 @default.
- W3207560024 hasConceptScore W3207560024C2777037409 @default.
- W3207560024 hasConceptScore W3207560024C2777129736 @default.
- W3207560024 hasConceptScore W3207560024C2777832160 @default.
- W3207560024 hasConceptScore W3207560024C2778283404 @default.
- W3207560024 hasConceptScore W3207560024C2779185760 @default.
- W3207560024 hasConceptScore W3207560024C2779758542 @default.
- W3207560024 hasConceptScore W3207560024C2780333948 @default.
- W3207560024 hasConceptScore W3207560024C71924100 @default.
- W3207560024 hasConceptScore W3207560024C90924648 @default.
- W3207560024 hasIssue "5" @default.
- W3207560024 hasLocation W32075600241 @default.
- W3207560024 hasOpenAccess W3207560024 @default.
- W3207560024 hasPrimaryLocation W32075600241 @default.
- W3207560024 hasRelatedWork W2415118119 @default.
- W3207560024 hasRelatedWork W2464060852 @default.
- W3207560024 hasRelatedWork W2795629650 @default.
- W3207560024 hasRelatedWork W2906438241 @default.
- W3207560024 hasRelatedWork W2999952146 @default.
- W3207560024 hasRelatedWork W3022896806 @default.
- W3207560024 hasRelatedWork W3126899443 @default.
- W3207560024 hasRelatedWork W3207560024 @default.
- W3207560024 hasRelatedWork W35794083 @default.
- W3207560024 hasRelatedWork W4285684549 @default.
- W3207560024 hasVolume "31" @default.
- W3207560024 isParatext "false" @default.
- W3207560024 isRetracted "false" @default.
- W3207560024 magId "3207560024" @default.
- W3207560024 workType "article" @default.